Tobam Cuts Stock Position in Humana Inc. (NYSE:HUM)

Tobam trimmed its stake in shares of Humana Inc. (NYSE:HUM) by 57.6% during the 4th quarter, HoldingsChannel.com reports. The firm owned 15,409 shares of the insurance provider’s stock after selling 20,974 shares during the quarter. Tobam’s holdings in Humana were worth $3,909,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of the stock. Atlas Brown Inc. lifted its stake in Humana by 0.6% in the 4th quarter. Atlas Brown Inc. now owns 6,352 shares of the insurance provider’s stock valued at $1,611,000 after buying an additional 38 shares in the last quarter. Moors & Cabot Inc. raised its holdings in shares of Humana by 2.5% during the third quarter. Moors & Cabot Inc. now owns 1,639 shares of the insurance provider’s stock valued at $519,000 after acquiring an additional 40 shares during the last quarter. Mather Group LLC. lifted its position in shares of Humana by 21.0% in the fourth quarter. Mather Group LLC. now owns 236 shares of the insurance provider’s stock valued at $60,000 after acquiring an additional 41 shares in the last quarter. OLD National Bancorp IN boosted its stake in shares of Humana by 1.8% in the third quarter. OLD National Bancorp IN now owns 2,613 shares of the insurance provider’s stock worth $828,000 after acquiring an additional 45 shares during the last quarter. Finally, Your Advocates Ltd. LLP raised its stake in Humana by 81.8% in the 3rd quarter. Your Advocates Ltd. LLP now owns 100 shares of the insurance provider’s stock valued at $32,000 after purchasing an additional 45 shares during the last quarter. Institutional investors and hedge funds own 92.38% of the company’s stock.

Humana Stock Performance

Shares of Humana stock opened at $279.63 on Friday. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.76 and a quick ratio of 1.76. The stock has a market capitalization of $33.67 billion, a price-to-earnings ratio of 24.77, a price-to-earnings-growth ratio of 2.21 and a beta of 0.56. The business has a 50-day moving average of $275.01 and a 200 day moving average of $299.65. Humana Inc. has a 12 month low of $213.31 and a 12 month high of $406.46.

Wall Street Analyst Weigh In

HUM has been the subject of a number of research reports. Truist Financial upped their target price on shares of Humana from $260.00 to $290.00 and gave the stock a “hold” rating in a report on Monday, January 6th. Morgan Stanley increased their price objective on shares of Humana from $288.00 to $301.00 and gave the company an “equal weight” rating in a report on Tuesday, December 17th. Wells Fargo & Company lowered their target price on Humana from $387.00 to $290.00 and set an “overweight” rating on the stock in a report on Monday, November 4th. TD Cowen increased their price target on Humana from $261.00 to $268.00 and gave the company a “hold” rating in a report on Monday, November 4th. Finally, Piper Sandler boosted their price objective on Humana from $270.00 to $288.00 and gave the stock a “neutral” rating in a research note on Wednesday, January 15th. Nineteen research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $297.68.

Insider Activity

In related news, insider Timothy S. Huval sold 3,703 shares of Humana stock in a transaction on Tuesday, December 31st. The stock was sold at an average price of $256.26, for a total value of $948,930.78. Following the completion of the transaction, the insider now directly owns 8,181 shares in the company, valued at approximately $2,096,463.06. This trade represents a 31.16 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 0.29% of the company’s stock.

Humana Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.